Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Trial Profile

Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs A-dmDT390-anti-CD3bisFv immunotoxin (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Angimmune
  • Most Recent Events

    • 15 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top